31.76
-0.06
(-0.19%)
May 23 - Close
NYSE
real-time data -
Disclaimer
Currency in USD
| Range | 31.34 - 31.86 |
| 52 week | 23.73 - 35.86 |
| Open | 31.44 |
| Vol / Avg. | 1.13M/1.53M |
| Mkt cap | 3.56B |
| P/E | 46.29 |
| Div/yield | 0.07/0.88 |
| EPS | 0.69 |
| Shares | 111.94M |
| Beta | 0.97 |
| Inst. own | 97% |
Events
Jul 29, 2013
Q2 2013 PerkinElmer Earnings Release
May 20, 2013
PerkinElmer at UBS Global Healthcare Conference
Apr 25, 2013
Q1 2013 PerkinElmer Earnings Conference Call -
Apr 24, 2013
Q1 2013 PerkinElmer Earnings Release
Mar 12, 2013
PerkinElmer at Barclays Healthcare Conference
|
More events from DailyFinance »
|
Key stats and ratios
| Q1 (Mar '13) | 2012 | |
| Net profit margin | 6.39% | 3.24% |
| Operating margin | 7.10% | 4.66% |
| EBITD margin | - | 19.12% |
| Return on average assets | 3.36% | 1.76% |
| Return on average equity | 6.86% | 3.62% |
| Employees | 7,500 | - |
| Carbon Disclosure Rating | - | 53/100 |
Address
Website links
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Research Reports - Reuters
Discussion Group - Google Finance
Volume delayed by 15 mins.
Advertisement
Description
PerkinElmer, Inc. is a provider of technology, services and solutions to the diagnostics, research, environmental, industrial and laboratory services markets. Through the Company�s advanced technologies, solutions, and services, it addresses issues related to health and safety of people and their environment. It operates in two segments: Human Health and Environmental Health. In February 2011, it acquired chemagen Biopolymer-Technologie AG (chemagen). In March 2011, it acquired ArtusLabs, Inc. (ArtusLabs). In March 2011, it acquired specified assets and assumed specified liabilities of ID Biological Systems, Inc. (IDB). In April 2011, it acquired CambridgeSoft Corporation (CambridgeSoft). In May 2011, it acquired Geospiza, Inc. (Geospiza). In May 2011, it acquired Labtronics, Inc. (Labtronics). In June 2011, it acquired Dexela Limited (Dexela). In November 2011, it acquired Caliper Life Sciences, Inc. (Caliper).
Officers and directors
| Robert F. Friel | Chairman of the Board, President, Chief Executive Officer | |
| Frank Anders Wilson CPA | Chief Financial Officer, Senior Vice President | |
| Daniel R. Marshak Ph.D. | Chief Scientific Officer, Senior Vice President, President - Emerging Diagnostics | |
| Joel S. Goldberg | Senior Vice President, General Counsel, Secretary | |
| John R. Letcher | Senior Vice President - Human Resources | |
| James Corbett | Senior Vice President, President - Diagnostics | |
| E. Kevin Hrusovsky | Senior Vice President, President - Life Sciences and Technology | |
| Maurice H. Tenney III | Senior Vice President, President - Environmental Health Business | |
| Andrew Okun | Chief Accounting Officer, Vice President | |
| Nicholas A. Lopardo | Lead Independent Director |